ZA9512B - Monohydrate of (E)-2'-deoxy-2'-(fluoromethylene)cytidine - Google Patents
Monohydrate of (E)-2'-deoxy-2'-(fluoromethylene)cytidineInfo
- Publication number
- ZA9512B ZA9512B ZA9512A ZA9512A ZA9512B ZA 9512 B ZA9512 B ZA 9512B ZA 9512 A ZA9512 A ZA 9512A ZA 9512 A ZA9512 A ZA 9512A ZA 9512 B ZA9512 B ZA 9512B
- Authority
- ZA
- South Africa
- Prior art keywords
- fluoromethylene
- cytidine
- deoxy
- monohydrate
- neoplastic
- Prior art date
Links
- 150000004682 monohydrates Chemical class 0.000 title abstract 2
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 title abstract 2
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 abstract 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17895294A | 1994-01-07 | 1994-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA9512B true ZA9512B (en) | 1995-09-11 |
Family
ID=22654587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9512A ZA9512B (en) | 1994-01-07 | 1995-01-03 | Monohydrate of (E)-2'-deoxy-2'-(fluoromethylene)cytidine |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0738273B1 (de) |
| JP (1) | JPH09511227A (de) |
| KR (1) | KR100330328B1 (de) |
| CN (1) | CN1043231C (de) |
| AT (1) | ATE186732T1 (de) |
| AU (1) | AU684604B2 (de) |
| CA (1) | CA2179987C (de) |
| DE (1) | DE69421721T2 (de) |
| DK (1) | DK0738273T3 (de) |
| ES (1) | ES2141330T3 (de) |
| FI (1) | FI114396B (de) |
| GR (1) | GR3032614T3 (de) |
| HU (1) | HU217849B (de) |
| IL (1) | IL112242A (de) |
| MX (1) | MX9500363A (de) |
| NO (1) | NO306409B1 (de) |
| NZ (1) | NZ279030A (de) |
| TW (1) | TW397838B (de) |
| WO (1) | WO1995018815A1 (de) |
| ZA (1) | ZA9512B (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1130363C (zh) | 1997-11-12 | 2003-12-10 | 三菱化学株式会社 | 嘌呤衍生物以及含有其作为有效成分的药物 |
| WO2000068231A1 (en) | 1999-05-11 | 2000-11-16 | Mitsubishi Chemical Corporation | Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA898567B (en) * | 1988-11-15 | 1990-08-29 | Merrell Dow Pharma | Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine,uridine and guanosine derivatives |
| FI95269C (fi) * | 1989-05-15 | 1996-01-10 | Squibb Bristol Myers Co | 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja |
| JPH0615557B2 (ja) * | 1990-02-19 | 1994-03-02 | ヤマサ醤油株式会社 | ２’―デオキシ―２’―メチリデンシチジンの２水和物結晶 |
| JP3265548B2 (ja) * | 1992-05-12 | 2002-03-11 | メレルファーマス−ティカルズ インコーポレイテッド | リボヌクレオチド還元酵素阻害剤の製法 |
-
1994
- 1994-12-13 AT AT95907232T patent/ATE186732T1/de not_active IP Right Cessation
- 1994-12-13 CN CN94194779A patent/CN1043231C/zh not_active Expired - Fee Related
- 1994-12-13 EP EP95907232A patent/EP0738273B1/de not_active Expired - Lifetime
- 1994-12-13 WO PCT/US1994/014648 patent/WO1995018815A1/en not_active Ceased
- 1994-12-13 DE DE69421721T patent/DE69421721T2/de not_active Expired - Fee Related
- 1994-12-13 HU HU9601848A patent/HU217849B/hu not_active IP Right Cessation
- 1994-12-13 NZ NZ279030A patent/NZ279030A/en unknown
- 1994-12-13 ES ES95907232T patent/ES2141330T3/es not_active Expired - Lifetime
- 1994-12-13 AU AU15532/95A patent/AU684604B2/en not_active Ceased
- 1994-12-13 JP JP7518503A patent/JPH09511227A/ja active Pending
- 1994-12-13 CA CA002179987A patent/CA2179987C/en not_active Expired - Fee Related
- 1994-12-13 KR KR1019960703658A patent/KR100330328B1/ko not_active Expired - Fee Related
- 1994-12-13 DK DK95907232T patent/DK0738273T3/da active
-
1995
- 1995-01-03 ZA ZA9512A patent/ZA9512B/xx unknown
- 1995-01-04 IL IL11224295A patent/IL112242A/xx not_active IP Right Cessation
- 1995-01-04 TW TW084100012A patent/TW397838B/zh not_active IP Right Cessation
- 1995-01-06 MX MX9500363A patent/MX9500363A/es unknown
-
1996
- 1996-07-05 FI FI962769A patent/FI114396B/fi active IP Right Grant
- 1996-07-05 NO NO962848A patent/NO306409B1/no unknown
-
2000
- 2000-02-09 GR GR20000400313T patent/GR3032614T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI962769L (fi) | 1996-07-05 |
| NO962848L (no) | 1996-09-06 |
| HU217849B (hu) | 2000-04-28 |
| CN1141045A (zh) | 1997-01-22 |
| DE69421721T2 (de) | 2000-04-27 |
| AU684604B2 (en) | 1997-12-18 |
| ATE186732T1 (de) | 1999-12-15 |
| WO1995018815A1 (en) | 1995-07-13 |
| TW397838B (en) | 2000-07-11 |
| DK0738273T3 (da) | 2000-04-17 |
| IL112242A0 (en) | 1995-03-30 |
| FI962769A0 (fi) | 1996-07-05 |
| GR3032614T3 (en) | 2000-05-31 |
| AU1553295A (en) | 1995-08-01 |
| HU9601848D0 (en) | 1996-09-30 |
| CA2179987C (en) | 1999-01-19 |
| NZ279030A (en) | 1997-05-26 |
| ES2141330T3 (es) | 2000-03-16 |
| NO306409B1 (no) | 1999-11-01 |
| EP0738273B1 (de) | 1999-11-17 |
| DE69421721D1 (de) | 1999-12-23 |
| IL112242A (en) | 2000-08-31 |
| CA2179987A1 (en) | 1995-07-13 |
| JPH09511227A (ja) | 1997-11-11 |
| EP0738273A1 (de) | 1996-10-23 |
| HUT75055A (en) | 1997-03-28 |
| NO962848D0 (no) | 1996-07-05 |
| KR100330328B1 (ko) | 2002-12-05 |
| MX9500363A (es) | 1998-04-30 |
| CN1043231C (zh) | 1999-05-05 |
| FI114396B (fi) | 2004-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO952228L (no) | Anvendelse av lamotrigin ved behandling av neurologiske lesjoner relatert til traumatiske skader | |
| CA2002648A1 (en) | 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | |
| GB9407305D0 (en) | Pharmaceutical compositions | |
| IL112242A (en) | Monohydrate of (E)-2'-deoxy-2'-(fluoromethylene)cytidine | |
| SE9500566L (sv) | L-platta | |
| TR199701212T1 (xx) | �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�. | |
| MX9603091A (es) | Intermediarios de cloropirimidina. | |
| EP0334361A3 (de) | Durch Acetylen, Cyan oder Allen substituierte Aristeromycin- oder Adenosin-Derivate | |
| ATE201680T1 (de) | 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze | |
| GB2340491A (en) | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | |
| EP0347852A3 (de) | Neplanocinderivate | |
| BR9811643A (pt) | Suplementação quìmica de osso | |
| MY124071A (en) | Treatment of viral disease in swine | |
| DE69836087D1 (de) | Kortikalknochenimplantat für wirbelfusion nach smith-robinson | |
| ES8704962A1 (es) | Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida. | |
| BR9916043A (pt) | Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes | |
| GR3034688T3 (en) | Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical compositions useful for the treatment of septic shock, and antipyretic and antiinflammatory pharmaceutical compositions | |
| EP0459176A3 (en) | Oligophosphates with antiviral activity | |
| BR0012380A (pt) | 2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples | |
| LTIP1943A (en) | Arylating agents, used in the treatment of cancerand disease caused by viral infection | |
| MY101613A (en) | Diabrotica larvicidal agents | |
| IT1271291B (it) | La melatonina quale riequilibratore fisiologico del rapporto linfocitario th1/th2 | |
| EP0210099A3 (en) | Use of n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamide in the treatment of parkinsons's disease | |
| UA23352A (uk) | beta- D- ГЛЮКОЗАМОHІЙHА СІЛЬ alРha-БРОМІЗОВАЛЕРІАHОВОЇ КИСЛОТИ, ЯКА МАЄ ПРОТИВІРУСHУ АКТИВHІСТЬ ВІДHОСHО ВІРУСУ ВЕЗИКУЛЯРHОГО СТОМАТИТУ, ВІРУСУ ПРОСТОГО ГЕРПЕСУ ТА КОРОHАВІРУСУ |